To investigate the mechanism by which dovitinib and OP449 decrease cell viability in T-ALL, we tested the effect of these treatments on c-MYC levels and on phosphorylation of kinases previously shown to have activity in T-ALL cell lines expressing wild-type NOTCH (JURKAT) or mutated NOTCH (RPMI-8402). This evidence concerns the gene MYC and acute lymphoblastic leukemia.